Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
BlackRock Health Sciences Trust II (BMEZ)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/26/2025: BMEZ (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type Stock | Historic Profit 9.4% | Avg. Invested days 69 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 03/26/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.51B USD | Price to earnings Ratio 71 | 1Y Target Price - |
Price to earnings Ratio 71 | 1Y Target Price - | ||
Volume (30-day avg) 323714 | Beta - | 52 Weeks Range 12.76 - 16.37 | Updated Date 03/29/2025 |
52 Weeks Range 12.76 - 16.37 | Updated Date 03/29/2025 | ||
Dividends yield (FY) 8.10% | Basic EPS (TTM) 0.21 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) - | Return on Equity (TTM) - |
Valuation
Trailing PE 71 | Forward PE - | Enterprise Value - | Price to Sales(TTM) 61.23 |
Enterprise Value - | Price to Sales(TTM) 61.23 | ||
Enterprise Value to Revenue 54.82 | Enterprise Value to EBITDA - | Shares Outstanding 101255000 | Shares Floating - |
Shares Outstanding 101255000 | Shares Floating - | ||
Percent Insiders 0.02 | Percent Institutions 26.49 |
Analyst Ratings
Rating - | Target Price - | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
BlackRock Health Sciences Trust II
Company Overview
History and Background
BlackRock Health Sciences Trust II (BMEZ) is a closed-end management investment company. It commenced operations on December 22, 2020. The Trust seeks to provide total return through a combination of current income, current gains, and long-term capital appreciation.
Core Business Areas
- Closed-End Fund: BMEZ operates as a closed-end fund, meaning it issues a fixed number of shares at its initial public offering. It does not continuously issue or redeem shares.
- Investment Management: BlackRock provides investment management services, including portfolio construction and security selection, focused on the health sciences sector.
Leadership and Structure
BMEZ is managed by BlackRock Advisors, LLC. The fund is overseen by a board of directors who are responsible for the overall governance of the fund.
Top Products and Market Share
Key Offerings
- Managed Investment Portfolio: BMEZ offers a managed portfolio invested primarily in equity securities of companies engaged in the health sciences and related industries. There isn't a direct 'market share' as it's a specific investment fund. Competitors include other health sciences-focused closed-end funds and ETFs.
Market Dynamics
Industry Overview
The health sciences industry is characterized by innovation, regulation, and demographic shifts. It includes pharmaceuticals, biotechnology, medical devices, healthcare providers, and related services. The industry is experiencing growth driven by aging populations, technological advancements, and increased healthcare spending.
Positioning
BMEZ is positioned as a specialized investment vehicle focused on the health sciences sector. Its competitive advantage lies in BlackRock's expertise in investment management and its access to research and resources.
Total Addressable Market (TAM)
The global healthcare market is projected to reach trillions of dollars. BMEZ, as a niche investment fund, targets a portion of this vast market by focusing on publicly traded health sciences companies. Its AUM represents a small fraction of the total healthcare market capitalization.
Upturn SWOT Analysis
Strengths
- Experienced Management Team (BlackRock)
- Focus on a growing sector (Health Sciences)
- Potential for high income and capital appreciation
- Diversified portfolio within the health sciences industry
Weaknesses
- Market Risk (Exposure to health sciences sector volatility)
- Management Fees (Expenses associated with fund management)
- Leverage Risk (Fund may employ leverage, increasing volatility)
- Closed-End Fund Structure (Shares may trade at a discount to NAV)
Opportunities
- Aging Global Population (Increased demand for healthcare products and services)
- Technological Advancements (Innovation in medical devices and pharmaceuticals)
- Emerging Markets (Growing healthcare spending in developing countries)
- Increased Healthcare Spending (Government and private sector investments)
Threats
- Regulatory Changes (Impact on drug pricing and approvals)
- Economic Downturns (Reduced healthcare spending)
- Competition (From other investment funds and healthcare companies)
- Patent Expirations (Impact on pharmaceutical company revenues)
Competitors and Market Share
Key Competitors
- HQH
- IHF
- XBI
Competitive Landscape
BMEZ competes with other health sciences funds based on investment strategy, performance, and fees. Its affiliation with BlackRock provides a brand advantage.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: BMEZ is a relatively new fund (launched in 2020). Assess its growth based on AUM changes and investment performance since inception.
Future Projections: Future growth depends on the performance of the health sciences sector and BlackRock's investment management capabilities. Analyst estimates are typically available from financial data providers.
Recent Initiatives: Review BMEZ's fact sheet and BlackRock's announcements for recent strategic initiatives.
Summary
BlackRock Health Sciences Trust II offers exposure to the health sciences sector with BlackRock's management expertise. Its performance depends on the health of the sector and its investment choices. The closed-end fund structure carries risks like trading at a discount. Investors should consider the fees and potential volatility.
Similar Companies
- HQH
- IHF
- XBI
- XLV
Sources and Disclaimers
Data Sources:
- BlackRock website
- Financial data providers (e.g., Bloomberg, Yahoo Finance)
- Company SEC Filings
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be based on individual risk tolerance and due diligence.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About BlackRock Health Sciences Trust II
Exchange NYSE | Headquaters New York, NY, United States | ||
IPO Launch date 2020-01-29 | CEO - | ||
Sector - | Industry - | Full time employees - | Website |
Full time employees - | Website | ||
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.